Despite an earlier downgrade to Market Perform by RBC this morning, Wells Fargo says Celgene (CELG -0.6%) looks attractive at current levels. After meeting with management, Wells says it's pleased with the way Q2 is going and thinks the stock could rally on the back of the E.U.'s label decision on Revlimid, and that the drug is positioned for solid growth.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 6:33PM)
at Investor's Business Daily (Feb 27, 2015)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Feb 26, 2015)
at Nasdaq.com (Feb 24, 2015)
at Zacks.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs